Table 3. Treatment-related adverse events.
| System organ class preferred team | AM (n=58), % | PM (n=74), % | P value | |||||
|---|---|---|---|---|---|---|---|---|
| All grades | Grades ≥3 | All grades | Grades ≥3 | All grades | Grade ≥3 | |||
| Any TEAEs | 86.21 | 31.03 | 86.49 | 21.62 | 0.96 | 0.22 | ||
| Blood and lymphatic system disorders | ||||||||
| Anemia | 65.52 | 15.52 | 58.11 | 10.81 | 0.39 | 0.43 | ||
| Leukopenia | 50.00 | 12.07 | 43.24 | 8.11 | 0.44 | 0.45 | ||
| Neutropenia | 41.38 | 12.07 | 40.54 | 8.11 | 0.92 | 0.45 | ||
| Thrombocytopenia | 29.31 | 6.90 | 27.03 | 6.76 | 0.77 | 0.98 | ||
| Lymphopenia | 24.14 | 6.90 | 29.73 | 2.70 | 0.48 | 0.25 | ||
| Hepatorenal toxicity | ||||||||
| ALT increased | 31.03 | 0 | 18.92 | 2.70 | 0.11 | 0.21 | ||
| AST increased | 22.41 | 0 | 14.86 | 2.70 | 0.27 | 0.21 | ||
| Creatinine increased | 17.24 | 0 | 9.46 | 0 | 0.19 | – | ||
| Urea nitrogen increased | 6.90 | 0 | 9.46 | 0 | 0.60 | – | ||
| Uric acid increased | 17.24 | 0 | 14.86 | 0 | 0.71 | – | ||
| Metabolism and nutrition disorders | ||||||||
| Decreased appetite | 20.69 | 0 | 33.78 | 0 | 0.10 | – | ||
| Hypoalbuminemia | 34.48 | 0 | 31.08 | 0 | 0.68 | – | ||
| Hypokalemia | 25.86 | 0 | 16.22 | 0 | 0.18 | – | ||
| Hypertriglyceridemia | 27.59 | 0 | 17.57 | 0 | 0.17 | – | ||
| Hyponatremia | 10.34 | 0 | 8.11 | 0 | 0.66 | – | ||
| GI disorders | ||||||||
| Nausea | 18.97 | 0 | 27.03 | 0 | 0.28 | – | ||
| Constipation | 3.45 | 0 | 4.05 | 0 | 0.86 | – | ||
| Vomiting | 17.24 | 0 | 13.56 | 0 | 0.19- | – | ||
| Diarrhea | 12.07 | 0 | 27.03 | 0 | 0.45 | – | ||
| General disorders | ||||||||
| Fatigue | 25.86 | 0 | 35.14 | 0 | 0.26 | – | ||
| Fever | 5.17 | 0 | 4.05 | 0 | 0.76 | – | ||
| Edema | 8.62 | 0 | 1.35 | 0 | 0.05 | – | ||
| Skin and subcutaneous tissue disorders | ||||||||
| Rash | 6.90 | 0 | 6.76 | 0 | 0.98 | – | ||
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GI, gastrointestinal; TEAEs, treatment-emergent adverse events.